REVERIE / ALLG CLL08
REVERIE / ALLG CLL08: A phase 2 study of venetoclax/rituximab (VenR) re-treatment in relapsed CLL patients with disease progression following VenR as their most recent line of therapy
Trial summary:
Receptor status / problem studied:
Inclusion criteria
Exclusion criteria
Open for recruitment
Trial Title
REVERIE / ALLG CLL08
Diagnosis
Leukaemia
Type of trial
Collaborative
Type of treatement
Haematology
Phase
II
Locations
Investigators
Principal Investigator